Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Immunogenicity of GR2102 in Healthy Adults
NCT06313697Phase 1Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2024
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GR2102 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Zhixiang Jintai. Primary endpoint: Adverse events. Started Mar 2024; status: recruiting.
02
Drugs
GR2102
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06313697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313697.